Related Experiment Video
Updated: Dec 15, 2025
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Chaperonin containing t-complex polypeptide 1 subunit 6A correlates with lymph node metastasis, abnormal
Ting Zhang1, Wang Shi2, Ke Tian1
1Department of Pulmonary and Critical Care Medicine, Affiliated Nanhua Hospital, University of South China, 336 South of Dongfeng Road, Hengyang, 421000, China.
Background:
This study aimed to investigate the correlation of chaperonin containing t-complex polypeptide 1 subunit 6A (CCT6A) expression with clinicopathological features and survival profiles in non-small cell lung carcinoma (NSCLC) patients.
Methods:
A total of 381 NSCLC patients with Tumor, Node, Metastasis (TNM) stage I-IIIA who underwent tumor resection were retrospectively screened. Immunohistochemistry staining and semi-quantitative scoring were used to evaluate CCT6A expression in tumor and adjacent tissues. Clinicopathological features were retrieved. Disease-free survival (DFS) and overall survival (OS) were calculated.
Results:
CCT6A expression was elevated in tumor tissue (CCT6A high 47.5% vs. low 52.5%) compared with adjacent tissue (CCT6A high 30.4% vs. low 69.6%) (P < 0.001), and ROC curve displayed that CCT6A could distinguish tumor tissue from adjacent tissue. Moreover, tumor CCT6A high expression was associated with lymph node metastasis (P = 0.001), elevated TNM stage (P = 0.002), and abnormal carcinoembryonic antigen (P = 0.022). Kaplan-Meier curves displayed that tumor CCT6A high expression was negatively correlated with DFS and OS (all P < 0.001). Cox's regression analysis disclosed that tumor CCT6A high expression independently predicted worse DFS (P < 0.001) (hazard ratio (HR) 1.659 (95% confidence interval (CI) 1.318-2.089)), and OS (P < 0.001) (HR 1.779 (95%CI 1.378-2.298)).
Conclusions:
CCT6A may present some clinical value in the management of NSCLC.
